The evolving role of avotermin in scar prevention

Expert Review of Dermatology, 05/10/2011

Avotermin is a novel human recombinant TGF–beta 3 protein that has been studied both in vitro and in vivo for its antiscarring properties. This article evaluates a recently published Phase II clinical trial focused on the role of avotermin as a prophylactically administered, scar–reducing biologic agent for the treatment of human incisional wounds.

Print Article Summary Cat 2 CME Report